JPRN-UMIN000004419已完成2 期
Phase II study of TS-1+PSK therapy as adjuvant chemotherapy during 2years against advanced gastric cancer. - Phase II study of TS-1+PSK therapy as adjuvant chemotherapy during 2years against advanced gastric cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patient with metachronous or synchronous multicancer 2.Patient who contraindicates to TS-1 3.Patient who requires continuous use of flucytosine, phenytoin or warfarin potassium 4.Patient who has experienced serious drug allergy over grade 3 in the past 5.Patient with serious complications including paralysis of intestine, ileus, interstitial pneumonitis, fibroid lung, uncontrollable diabetes mellitus, heart insufficiency, renal insufficiency or hepatic insufficiency 6.Patient with diarrhea (watery stool) 7.Patient who is pregnant or in lactation, or wish to become pregnant during this study 8.Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge
研究者
相似试验
已完成
2 期
Phase II study of TS-1 chemotherapy as adjuvant treatment after resection of hepatic metastases from colorectal cancerliver metastases of colorectal cancerJPRN-UMIN000001498agoya Surgical Oncology Group60
已完成
2 期
A phase II feasibility trial of TS-1/PSK therapy as adjuvant chemotherapy for gastric cancer with TS-1/CDDP as neoadjuvant chemotherapy.Gastric cancerJPRN-UMIN000004266Department of Gastroenterological Surgery Graduate School of Medicine Osaka University10
已完成
不适用
Phase II study of neoadjuvant chemotherapy of TS-1, CDDP and Paclitaxel for resectable large type 3 or type 4 gastric cancerAdvanced gastric cancerJPRN-UMIN000014332School of Medicine, Keio University40
已完成
不适用
A phase II trial of TS-1/CDDP as neoadjuvant chemotherapy against resectable gastric cancer.Gastric cancerJPRN-UMIN000004466Toho University110
已完成
2 期
Phase II trial of S-1 monotherapy as adjuvant chemotherapy in triple negative breast cancer patients who did not achieve pathological complete response after neoadjuvant chemotherapyBreast cancerJPRN-UMIN000004340Kitasato University School of Medicine30